Literature DB >> 15339674

KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication.

Alessandro Beghini1, Carla B Ripamonti, Roberto Cairoli, Giovanni Cazzaniga, Patrizia Colapietro, Francesca Elice, Gianpaolo Nadali, Giovanni Grillo, Oskar A Haas, Andrea Biondi, Enrica Morra, Lidia Larizza.   

Abstract

BACKGROUND AND OBJECTIVES: Mutations of KIT receptor tyrosine kinase are involved in the constitutive activation and development of human hematologic malignancies. Gain-of-function mutations in the second intracellular kinase domain (TK2) and in the juxtamembrane domain are described in patients with core binding factor acute myeloid leukemia (CBFL) and are associated with leukocytosis. We evaluated the incidence of KIT mutation in 52 adult patients with de novo CBFL and in 49 FLT3/ITD-negative childhood patients with de novo acute myeloid leukemia (AML), excluding cases of acute promyelocytic leukemia. DESIGN AND METHODS: In order to analyze the role of KIT in CBFL we examined the KIT mutations in 52 adult CBFL, including 15 previously reported patients, and in 49 non-APL childhood AML patients using sensitive detection methods. We correlated our findings with the presence of trisomy 4 and investigated the relationship of the extra chromosome 4 with KIT mutations.
RESULTS: Several kinds of gain-of-function KIT mutations were found in 24 of the 52 (46.1%) adult CBFL cases and 6 of the 49 (12.2%) non-APL childhood AML patients. KIT mutations were detected in 4 of the 8 adult patients and one childhood AML case bearing trisomy of chromosome 4 as either the sole cytogenetic aberration or a karyotypic aberration additional to t(8;21). In three of the trisomy 4 cases we demonstrated that trisomy 4 leads to duplication of the KIT mutated allele. INTERPRETATION AND
CONCLUSIONS: These results underline that the KIT gene is activated in AML characterized by distinct cytogenetic and molecular genetic patterns and represents the most frequently mutated target in adult CBFL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339674

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  36 in total

1.  KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.

Authors:  Ling Zhao; Jan J Melenhorst; Lemlem Alemu; Martha Kirby; Stacie Anderson; Maggie Kench; Shelley Hoogstraten-Miller; Lauren Brinster; Yasuhiko Kamikubo; D Gary Gilliland; P Paul Liu
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits.

Authors:  Matteo Brioschi; John Fischer; Roberto Cairoli; Stefano Rossetti; Laura Pezzetti; Michele Nichelatti; Mauro Turrini; Francesca Corlazzoli; Barbara Scarpati; Enrica Morra; Nicoletta Sacchi; Alessandro Beghini
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

Review 3.  Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.

Authors:  Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2006-05       Impact factor: 2.490

4.  Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia.

Authors:  Lara Tickenbrock; Sina Hehn; Bülent Sargin; Georg Evers; Pavankumar Reddy Ng; Chunaram Choudhary; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve
Journal:  Int J Hematol       Date:  2008-07-31       Impact factor: 2.490

5.  Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis.

Authors:  Oscar Fuster; Eva Barragán; Pascual Bolufer; José Cervera; Maria José Larráyoz; Antonio Jiménez-Velasco; Joaquín Martínez-López; Ana Valencia; Federico Moscardó; Miguel Angel Sanz
Journal:  J Mol Diagn       Date:  2009-07-30       Impact factor: 5.568

6.  Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation.

Authors:  Jutong Si; Steven J Collins
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

7.  Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.

Authors:  Anindya Chatterjee; Joydeep Ghosh; Baskar Ramdas; Raghuveer Singh Mali; Holly Martin; Michihiro Kobayashi; Sasidhar Vemula; Victor H Canela; Emily R Waskow; Valeria Visconte; Ramon V Tiu; Catherine C Smith; Neil Shah; Kevin D Bunting; H Scott Boswell; Yan Liu; Rebecca J Chan; Reuben Kapur
Journal:  Cell Rep       Date:  2014-11-13       Impact factor: 9.423

8.  Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.

Authors:  Hiroyuki Kawagoe; Gerard C Grosveld
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

9.  Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.

Authors:  Kim Klein; Gertjan Kaspers; Christine J Harrison; H Berna Beverloo; Ardine Reedijk; Mathilda Bongers; Jacqueline Cloos; Andrea Pession; Dirk Reinhardt; Martin Zimmerman; Ursula Creutzig; Michael Dworzak; Todd Alonzo; Donna Johnston; Betsy Hirsch; Michal Zapotocky; Barbara De Moerloose; Alcira Fynn; Vincent Lee; Takashi Taga; Akio Tawa; Anne Auvrignon; Bernward Zeller; Erik Forestier; Carmen Salgado; Walentyna Balwierz; Alexander Popa; Jeffrey Rubnitz; Susana Raimondi; Brenda Gibson
Journal:  J Clin Oncol       Date:  2015-11-16       Impact factor: 44.544

10.  Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.

Authors:  Lina Han; Jan Jacob Schuringa; André Mulder; Edo Vellenga
Journal:  Ann Hematol       Date:  2010-04-13       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.